Hints and tips:
...British monarch, George V at the Empire Exhibition in London, and the first commemorative stamps being issued in Great Britain....
...Enter a new Spac. Arrival is merging with Kensington Capital Acquisition Corp V, paying a huge premium in order to add $300mn to its balance sheet....
...Bhan said India would probably do its best to honour its international commitments to bolster its reputation as a pharma power....
...Fund managers were more downbeat than last month about the prospects for a swift economic rebound from the virus. The proportion expecting a V-shaped recovery fell to 14 per cent from 18 per cent....
...The V traced by US indices heavily driven by tech and pharma stocks is appropriately narrow. The S&P 500 is down only 7.6 per cent since the pandemic hit the US and Europe....
...A strong retail performance is building hopes for a V-shaped economic recovery but exporters are still suffering, she writes....
...As a reminder, Banks account for 15% of MSCI Europe’s DPS, followed by Energy (11%), Pharma (10%) and Insurance (8%). • Updates to follow. Requests, complaints and so on can go in the comment box....
...We think valuation already largely reflects a strong v-shaped recovery and so we adopt a more cautious stance on the shares. Sales densities likely to be lower in high traffic locations....
...100’s still underperforming the global death toll by 1,188 percentage points....
...“The sheer number of changes that have been made in such a short period of time are themselves problematic.” He has a point, one that his predecessor, David Kappos, would agree with....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...S Dr Dave Mead Director of Business Development, Novozymes BioPharma UK Harriet Fear Chief Executive, One Nucleus Dr Anthony Holmes Chief Executive, Optasia Medical Katherine Taylor Acting Chief...
...Market sentiment had been better in earlier trading following a rebound on Wall Street. The S&P 500 rose 0.7 per cent, helped by some encouraging earnings reports, after losing 2.7 per cent last week....
...“UCB has become the latest focus of inquiries by Chinese officials in a growing clampdown on drug pricing and marketing practices in the country.”...
...Belgian drugmaker UCB said last week it had also been as been visited by Chinese authorities....
...Separately, Ernst & Young predicted a wave of acquisitions in the biotech sector driven by big pharma companies’ hunger for new products. Belgium’s UCB rose 1.6 per cent to €26.13....
...Following Merck’s bid for Serono, UCB of Belgium yesterday launched a €4.4bn bid for Schwarz Pharma. Analysts say Shire could be a target for US peers Medlmmune or Forest Labs....
International Edition